Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GEN1055

Monoclonal antibody · Agonist of OX40 (CD134) (TNFRSF4) · developed by Genmab

Phase 1/2 Most advanced trial (none active)
GMAB Developer

What is GEN1055?

GEN1055 is a hexabody-based agonistic monoclonal antibody that binds the co-stimulatory receptor OX40 (TNFRSF4) on T lymphocytes. Binding forms a hexamer that clusters OX40, promoting proliferation of memory and effector T cells and inhibiting regulatory T cells in the tumor microenvironment. It is being studied in malignant solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
OX40 (CD134) (TNFRSF4)
Mechanism
Agonist of OX40 (CD134) (TNFRSF4)
Pathways
T-cell activation and proliferation, Treg suppression in the tumor microenvironment
Therapy area
Oncology
Developer
Genmab (GMAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Malignant Solid Tumor

Other drugs acting on TNFRSF4

More from Genmab

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind GEN1055

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.